Please contact Scott Hall at email@example.com or 202-463-5817.
Kasie Brill is the vice president of brand protection and strategic initiatives at the U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC) and the Executive Director of the Global Brand Council. Kasie advocates for the protection of IP rights both online and in physical markets with a special focus on designing public policy solutions to combat counterfeit goods.
Prior to joining the Global Intellectual Property Center, Kasie served as an advisor to private sector clients fighting illegal online pharmacies. She also served as law clerk to The Honorable C. Ray Mullins, Chief Judge for the United States Bankruptcy Court for the Northern District of Georgia, Atlanta Division.
Kasie is a graduate of both Michigan State University and the Indiana University Maurer School of Law. During law school, Kasie served as President of the Student Bar Association, on the Executive Board of the Sherman Minton Moot Court, Law Alumni Board, Admissions Committee, and 2012 Class Campaign for Excellence. Involved in various student and volunteer organizations, upon graduation, Kasie received the honor of Outstanding Contribution to Student Life. She also worked as a research assistant on issues of globalization with a specialization on the global impact of counterfeit luxury goods.
Kasie has a wide-range of expertise in multiple disciplines. She worked for a national advertising agency, and in a variety of federal government positions including work on Capitol Hill, at the United States Supreme Court, and at the Federal Judicial Center.
Kasie received her B.A. in Communication and Business magna cum laude from Michigan State University in 2008. While an undergraduate, Kasie was recognized by MSU faculty as Most Outstanding Senior.
Kasie is a young leader on the Indiana University Maurer School of Law’s Washington D.C. Alumni Chapter and participates as a member of the Junior League of Washington.
Global Innovation Policy Center @globalIPcenter 13h
While there are currently 19 vaccines in the clinical stages of evaluation by various companies, @pfizer and @BioNTech_Group have taken a unique approach to develop and test a potential #COVID19 vaccine. https://t.co/VG3nb5Rg2V #DiscoverAndDeliver https://t.co/VG3nb5Rg2V